INKEF leads €64 million Series B financing round in Cardior
Berlin — INKEF Capital led the consortium of investors in the €64 million Series B financing round investment in Hanover-based Cardior Pharmaceuticals. — In addition to lead investor INKEF, new investors Fund+, Sunstone, Hadean Ventures and Coparion participated in the round. In addition, existing investors such as LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds also participated in the financing round. In connection with the financing, representatives from INKEF, Fund+ and Sunstone will join the company’s advisory board.
Cardior Pharmaceuticals is a leading biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics to prevent, treat and reverse heart disease. The company’s mission is to provide patients with novel therapeutics and diagnostics that will have a lasting impact on the treatment of heart disease worldwide.
“We believe ncRNAs can fundamentally change the treatment of heart disease by preventing, repairing and reversing damage to cardiac tissue. We thank our new and existing investors for their support and their confidence in our ability to achieve our goal,” said Dr. Claudia Ulbrich (photo), Chief Executive Officer and Co-Founder of Cardior.
INKEF Capital is an Amsterdam-based investment fund with a portfolio of more than 45 companies in the healthcare and technology sectors.
Advisor INKEF + Investor Consortium: YPOG
Dr. Martin Schaper (Lead Partner), Partner
Dr. Malte Bergmann, Partner
Dr. Martyna Sabat, Senior Associate
Dr. Ansgar Frank, Associated Partner
Ann-Kristin Lochmann, Senior Associate
Pia Meven, Associate
Jonas Huth, Associate
Lukas Schmitt, Associate
The law firm KNPZ (Dr. Kai Plath, Matthias Struck and Jan Schäfer) advised on the transaction alongside the YPOG team in the IP area.
YPOG is a specialist tax and commercial law firm, operating in the core areas of corporate, funds, litigation, tax, transactions, IT/IP and notarial services. The YPOG team advises a wide variety of clients. These include emerging technology companies and family-run medium-sized enterprises as well as corporations and private equity/venture capital funds. Since its foundation in 2017, the firm has become one of the leading addresses for venture capital, private equity and fund structuring in Germany. The firm and its partners are nationally and internationally ranked by JUVE, Best Lawyers, Legal 500, Focus, and Chambers and Partners. Today, YPOG employs more than 70 experienced lawyers, tax advisors, tax specialists and a notary in three offices in Berlin, Hamburg and Cologne. www.ypog.law